[go: up one dir, main page]

CA2219867A1 - Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique - Google Patents

Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique Download PDF

Info

Publication number
CA2219867A1
CA2219867A1 CA002219867A CA2219867A CA2219867A1 CA 2219867 A1 CA2219867 A1 CA 2219867A1 CA 002219867 A CA002219867 A CA 002219867A CA 2219867 A CA2219867 A CA 2219867A CA 2219867 A1 CA2219867 A1 CA 2219867A1
Authority
CA
Canada
Prior art keywords
cells
proteasome
lac
inhibitor
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002219867A
Other languages
English (en)
Inventor
Jiangping Wu
Xin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Centre Hospitalier de lUniversite de Montreal CHUM
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002219867A priority Critical patent/CA2219867A1/fr
Priority to JP52505499A priority patent/JP2001508465A/ja
Priority to EP98951135A priority patent/EP0967976A1/fr
Priority to AU97318/98A priority patent/AU770798B2/en
Priority to PCT/CA1998/001010 priority patent/WO1999022729A1/fr
Priority to CA002276013A priority patent/CA2276013A1/fr
Publication of CA2219867A1 publication Critical patent/CA2219867A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur l'utilisation d'un inhibiteur du protéasome pour provoquer l'apoptose chez des cellules prolifératives. Différentes cibles fonctionnelles du protéasome sont mises en évidence, et le mode d'action de diverses protéines dans le cycle cellulaire et l'apoptose est précisé. On décrit les effets dudit inhibiteur du protéasomoe sur la fonction mitonchondriale et la production de monoxyde d'azote ainsi qu'une épreuve d'identification des inhibiteurs du protéasome.
CA002219867A 1997-10-31 1997-10-31 Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique Abandoned CA2219867A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002219867A CA2219867A1 (fr) 1997-10-31 1997-10-31 Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique
JP52505499A JP2001508465A (ja) 1997-10-31 1998-10-29 ガン、炎症、自己免疫疾患、移植片拒絶反応および敗血症性ショックを処置するためのプロテアソーム阻害因子の使用
EP98951135A EP0967976A1 (fr) 1997-10-31 1998-10-29 Utilisation d'inhibiteurs de proteasomes dans le traitement du cancer, de l'inflammation, de maladies autoimmunes, du rejet du greffon et du choc septique
AU97318/98A AU770798B2 (en) 1997-10-31 1998-10-29 The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
PCT/CA1998/001010 WO1999022729A1 (fr) 1997-10-31 1998-10-29 Utilisation d'inhibiteurs de proteasomes dans le traitement du cancer, de l'inflammation, de maladies autoimmunes, du rejet du greffon et du choc septique
CA002276013A CA2276013A1 (fr) 1997-10-31 1998-10-29 Utilisation d'inhibiteurs de pro-teasomes dans le traitement du cancer, de l'inflammation, de ma-ladies autoimmunes, du rejet du greffon et du choc septique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002219867A CA2219867A1 (fr) 1997-10-31 1997-10-31 Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique

Publications (1)

Publication Number Publication Date
CA2219867A1 true CA2219867A1 (fr) 1999-04-30

Family

ID=4161712

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002219867A Abandoned CA2219867A1 (fr) 1997-10-31 1997-10-31 Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique

Country Status (5)

Country Link
EP (1) EP0967976A1 (fr)
JP (1) JP2001508465A (fr)
AU (1) AU770798B2 (fr)
CA (1) CA2219867A1 (fr)
WO (1) WO1999022729A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2726367C2 (ru) * 2016-03-28 2020-07-13 Пресидж Байосайенсиз, Инк. Фармацевтические комбинации для лечения злокачественной опухоли

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142647A0 (en) * 1998-10-20 2002-03-10 Millenium Pharmaceuticals Inc A method and kit for measuring proteasome activity
JP2011195590A (ja) * 1999-10-20 2011-10-06 Osteoscreen Inc 骨および毛成長を刺激するためのプロテアソーム活性のインヒビター
WO2001067100A1 (fr) * 2000-03-03 2001-09-13 University Of South Florida Participation de la decomposition de bax a la survie et la progression des tumeurs
IL152719A0 (en) 2000-06-28 2003-06-24 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification
AU2002218133A1 (en) 2000-10-12 2002-04-22 Viromics Gmbh Agents for the treatment of viral infections
WO2002080907A1 (fr) * 2001-04-03 2002-10-17 Millennium Pharmaceuticals, Inc. Combinaison d'analogue de lactacystine et de medicament immunosuppresseur permettant la prolongation de la survie d'une allogreffe
EP1392355B1 (fr) 2001-05-21 2007-02-14 Alcon, Inc. Utilisation d'inhibiteurs de proteasome pour traiter des secheresses de l'oeil
US7112588B2 (en) 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
EP1492545B1 (fr) 2002-04-05 2010-09-15 ViroLogik GmbH Agent de traitement d'infections par flaviviridae
DE10217254A1 (de) 2002-04-15 2003-10-23 Proteosys Ag Verwendung von Substanzen zur Behandlung von Tumoren
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
WO2004043374A2 (fr) 2002-11-06 2004-05-27 Dana-Farber Cancer Institute, Inc. Procedes et compositions de traitement du cancer au moyen d'inhibiteurs de la proteasome
US20050049294A1 (en) 2003-06-20 2005-03-03 Michael Palladino Methods of using [3.2.0] heterocyclic compounds and analogs thereof
ZA200600473B (en) * 2003-06-20 2007-04-25 Univ California Salinosporamides and methods for use thereof
EP1720559A4 (fr) * 2004-02-06 2009-07-22 Univ Chicago Facteur anti-inflammatoire, cytoprotecteur pouvant etre derive d'un organisme probiotique
JP5274248B2 (ja) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 酸化窒素治療及び医生物的応用のための酸化窒素放出粒子
DE102006026464A1 (de) * 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
WO2008063513A2 (fr) * 2006-11-13 2008-05-29 Trustees Of Columbia University In The City Of New York Inhibiteurs de protéasome sélectifs pour traiter le diabète
EP2088205A1 (fr) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10 : marqueur de diagnostic et cible thérapeutique de rejet chronique
WO2009140287A1 (fr) 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Dérivés de salinosporamide à utiliser en tant qu'inhibiteurs des protéasomes
JP2010004750A (ja) * 2008-06-24 2010-01-14 Institute For Rheumatic Diseases Co Ltd 自己免疫疾患による組織傷害の発症または発症可能性の診断方法、およびその利用
KR20160091440A (ko) * 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
EP2467173B8 (fr) 2009-08-21 2019-06-19 Novan, Inc. Pansements, procédés d'utilisation de ceux-ci et procédés de formation de ceux-ci
CN102711729B (zh) 2009-08-21 2015-04-01 诺万公司 局部用凝胶
DE102010039631A1 (de) * 2010-08-22 2012-02-23 Ulrich Schubert Pharmazeutische Zusammensetzungen mit immunmodulatorischen Eigenschaften
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118819A2 (fr) 2011-02-28 2012-09-07 Novan, Inc. Particules de silice modifiées par des groupements s-nitrosothiols libérant de l'oxyde nitrique et procédés de fabrication associés
WO2012164398A2 (fr) * 2011-06-01 2012-12-06 Netherlands Cancer Institute Modulation du système ubiquitine-protéasome (ups)
KR101757373B1 (ko) * 2015-07-24 2017-07-26 울산과학기술원 프로테아좀 억제제 스크리닝용 조성물 및 이를 이용한 프로테아좀 억제제 스크리닝 방법
WO2024192873A1 (fr) * 2023-03-20 2024-09-26 杭州天玑济世生物科技有限公司 Utilisation d'un composé à petites molécules ayant une structure de naphtylamine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155554A1 (fr) * 1993-02-10 1994-08-18 Alfred L. Goldberg Role de la proteolyse atp-ubiquitine-dependante dans la presentation de l'antigene a restriction mhc-1; inhibiteurs de celui-ci
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) * 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5834487A (en) * 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2726367C2 (ru) * 2016-03-28 2020-07-13 Пресидж Байосайенсиз, Инк. Фармацевтические комбинации для лечения злокачественной опухоли
US11135198B2 (en) 2016-03-28 2021-10-05 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
US12121508B2 (en) 2016-03-28 2024-10-22 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
US12171744B2 (en) 2016-03-28 2024-12-24 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer

Also Published As

Publication number Publication date
JP2001508465A (ja) 2001-06-26
AU9731898A (en) 1999-05-24
EP0967976A1 (fr) 2000-01-05
AU770798B2 (en) 2004-03-04
WO1999022729A1 (fr) 1999-05-14

Similar Documents

Publication Publication Date Title
AU770798B2 (en) The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US20020049157A1 (en) Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
Wang et al. Role of proteasomes in T cell activation and proliferation
Stangl et al. Long‐term up‐regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin–proteasome pathway
Luo et al. A PROTEASOME INHIBITOR EFFECTIVELY PREVENTS MOUSE HEART ALLOGRAFT REJECTION1
Mandic et al. Calpain-mediated Bid cleavage and calpain-independent Bak modulation: two separate pathways in cisplatin-induced apoptosis
Pendergraft III et al. Proteinase 3 sidesteps caspases and cleaves p21Waf1/Cip1/Sdi1 to induce endothelial cell apoptosis
Klisovic et al. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines
CN109999041A (zh) 吩噻嗪衍生物对malt1蛋白酶的选择性抑制
Schliep et al. Functional evaluation of the role of inhibitor of apoptosis proteins in chronic lymphocytic leukemia
US7786170B2 (en) Histone deacetylase inhibitor enhancement of trail-induced apoptosis
Wall et al. Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh.
EP1545287B1 (fr) Composes vasoregulateurs et procedes concernant leur utilisation
CA2276013A1 (fr) Utilisation d'inhibiteurs de pro-teasomes dans le traitement du cancer, de l'inflammation, de ma-ladies autoimmunes, du rejet du greffon et du choc septique
Shav-Tal et al. Enhanced proteolysis of pre-mRNA splicing factors in myeloid cells
CA2372316A1 (fr) Utilisation d'inhibiteurs de proteasome pour le traitement du cancer, des inflammations, des maladies autoimmunes, des rejets de greffes, et du choc septique
Shi et al. Potential effects of PKC or protease inhibitors on acute pancreatitis-induced tissue injury in rats
WO2012170113A1 (fr) Blocages des interactions protéine d'échafaudage/kinase et applications dans le traitement du cancer
EP1814570A2 (fr) Methodes visant a reduire l'expression genique induite par le hif-1
US20110065643A1 (en) Clusterin Pharmaceuticals and Treatment Methods Using the Same
US7005269B2 (en) ERAAP modulators regulate immune responses
JP2005537292A (ja) 内皮機能障害の治療および／または低用量プロテアソーム阻害剤療法におけるプロテアソーム阻害剤の使用
Zhang Development of cyclophilin inhibitors for the treatment of pancreatitis
WO2012068344A2 (fr) Régulation de cathepsine l par la dendrine de son facteur de transcription
CN110496128A (zh) 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20040126